ArticleInternational journal of cardiology. Heart & vasculature2024
Healthcare utilization and expenditures in patients with tricuspid regurgitation: A population-based cohort study.
Article in International journal of cardiology. Heart & vasculature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Healthcare cost and utilization before and after the development of significant tricuspid regurgitation by age, sex and race.Journal of comparative effectiveness research · 2026Article
- Recent highlights from theInternational journal of cardiology. Heart & vasculature · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tricuspid regurgitation (TR) is the most common tricuspid valve (TV) condition. However, little is known about the prevalence, clinical significance, or economic impact of TR, including TR with comorbid heart failure (HF). Materials and Methods: Taiwan's National Health Insurance Research Database was used to perform a retrospective cohort study about patients with TR. The study included patients over the age of 18 with TR who provided data from January 2017 to December 2019. The cohorts were divided into six groups based on whether significant TR was present (sTR) or not (nsTR), and whether HF was present (HF) or not present (noHF), or inconclusive (incHF). Results: This study included 21,051 patients with TR. Patients with nsTR-noHF had an annualized healthcare burden of 0.36 all-cause hospitalizations, 3.26 days length of stay (LOS), and NTD 66,834 in expenses. sTR led to significant increases in healthcare utilization and expenditures. The annualized economic burden for sTR-noHF patients increased to 1.03 all-cause hospitalizations, 10.75 days LOS, and NTD 210,842 in expenses. Patients with sTR and HF had significantly higher healthcare utilization and expenditures; patients with sTR-HF had an annualized economic burden of 2.46 all-cause hospitalizations, 33.18 days LOS, and NTD 480,711 in spending. Conclusion: TR patients with HF or sTR are more likely to be hospitalized, use more healthcare resources, and face higher financial burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.